<DOC>
	<DOCNO>NCT03084250</DOCNO>
	<brief_summary>The HBeAg positive CHB subject cirrhosis , platelet &lt; 14.0*104/mm3 ，HBVDNA &gt; 2000IU/ml , randomize two group . The subject go group A treat nucleotide analogue ( NA ) combination peginterferon alfa-2a,180μg/week 48 week . The subject go group B treat nucleotide analogue ( NA ) 48 week .</brief_summary>
	<brief_title>The Investigation Peginterferon Alfa-2a Optimal Chronic Hepatitis B Patients Who Have High Risk HCC</brief_title>
	<detailed_description>This study prospective , randomize , open-label study . The HBeAg positive CHB subject cirrhosis , platelet &lt; 14.0*104/mm3 ，HBVDNA &gt; 2000IU/ml , randomize two group . The subject go group A treat nucleotide analogue ( NA ) combination peginterferon alfa-2a,180μg/week 48 week . The subject go group B treat nucleotide analogue ( NA ) 48 week .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Adefovir</mesh_term>
	<mesh_term>Adefovir dipivoxil</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>1 . Male female patient age ≥18 ≤65 year ; 2 . There evidence HBsAg HBeAg positive 6 month HBsAb HBeAb negative ; cirrhosis , platelet &lt; 14.0*104/mm3 ，HBVDNA &gt; 2000IU/ml ; 3 . Women without ongoing pregnancy breast feed woman men willing take effective contraceptive measure treatment ; 4 . Agree participate study sign patient inform consent form . 1 . Treated immunosuppressant , immunomodulator , Systemic cytotoxic drug , herb HBIg within 6 month prior first dose treatment ; 2 . ALT≥10 X ULN total bilirubin ≥2 X ULN ; 3 . Allergic history interferon ; 4 . Coinfection active hepatitis A , hepatitis C , hepatitis D and/or human immunodeficiency virus ( HIV ) ; 5 . ChildPugh score &gt; 7 ; 6 . History evidence medical condition associate chronic liver disease viral hepatitis ( e.g. , hemochromatosis , autoimmune hepatitis , metabolic liver disease , alcoholic liver disease , toxin exposure , thalassemia ) ; 7 . Pregnant breastfeeding Women ; 8 . Consuming alcohol excess 20g/day woman 30g/day men within 6 month prior enrollment drug take history ; 9 . ANC ( absolute neutrophil count ) &lt; 1.5x 10^9/L PLT ( platelet count ) &lt; 90x 10^9/L 10 . Creatinine upper limit normal ; 11 . History severe psychiatric disease , especially depression . Severe psychiatric disease define major depression psychosis treat antidepressant medication major tranquilizer therapeutic dos respectively time prior 3 month history follow : suicidal attempt hospitalization psychiatric disease , period disability due psychiatric disease ; 12 . History immunologically mediate disease , ( e.g. , inflammatory bowel disease , idiopathic thrombocytopenic purpura , lupus erythematosus , autoimmune hemolytic anemia , scleroderma , rheumatoid arthritis etc . ) ; 13 . History esophageal varix bleed evidence esophageal varix bleed symptom consistent decompensated liver disease ; 14 . History severe cardiac disease ( e.g. , New York Heart Association Functional Class III IV , myocardial infarction within 6 month , ventricular tachyarrhythmias require ongoing treatment , unstable angina significant cardiovascular disease ) ; 15 . Hemodialysis patient patient renal insufficiency ; 16 . History severe seizure disorder current anticonvulsant use ; 17 . Major organ transplantation evidence severe illness , malignancy , condition , would make patient , opinion investigator , unsuitable study ; 18 . History thyroid disease poorly control prescribed medication ; 19 . Evidence severe retinopathy clinically relevant ophthalmologic disorder ; 20 . History severe disease evidence severe disease illness condition investigator believe patient suitable join study ; 21 . Patients include another trial give investigational drug within 12 week prior screen ; 22 . AFP ( alpha feto protein ) &gt; 50ng/ml and/or evidence hepatocellular carcinoma ; 23 . Patients treated Telbivudine ; 24 . Other disease exclusive consider investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>